View Older Stories View More Recent Stories
-
Truist Securities Reiterates Buy Rating on Insulet Corporation (PODD), CFO transition seed as a modest surprise
-
Insulet Corporation (PODD) PT Raised to $360 at Piper Sandler
-
This medical stock is JPMorgan's Top SMid Cap Pick
-
Piper Sandler on calls with diabetes clinicians
-
Oppenheimer Starts Insulet Corporation (PODD) at Outperform
-
Insulet Corporation (PODD) PT Raised to $300 at Barclays
-
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital
-
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group
-
Insulet Corporation (PODD) PT Raised to $353 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $375 at Jefferies
-
Insulet (PODD) Tops Q2 EPS by 25c
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
Truist Securities Starts Insulet Corporation (PODD) at Buy
-
Insulet Corporation (PODD) PT Raised to $379 at TD Cowen After a Stellar 1Q
-
Goldman Sachs Starts Insulet Corporation (PODD) at Buy
-
Insulet Corporation (PODD) PT Raised to $360 at Raymond James
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Edwards Lifesciences (EW) Added as Top Pick at Citi, PODD Removed
-
'Insulet Corporation (PODD) is Our Top Pick in Diabetes'; PT Raised to $375 at Bernstein
-
Wolfe Research Upgrades Insulet Corporation (PODD) to Outperform
-
Piper Sandler on Insulet Corporation (PODD): 'Strong Update Across the Board'
-
Insulet Corporation (PODD) PT Raised to $331 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $330 at BTIG
-
Insulet (PODD) Tops Q1 EPS by 23c
-
William Blair Reiterates Outperform Rating on Insulet Corporation (PODD)
-
Canaccord Genuity Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet (PODD) Appoints Ashley McEvoy as President and CEO
-
Insulet's (PODD) RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
-
Insulet (PODD) Announces Pricing of Senior Notes Due 2033
-
Insulet (PODD) Announces Proposed $450M Financing Transactions
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
RBC Capital Starts Insulet Corporation (PODD) at Outperform
-
Insulet Corporation (PODD) PT Raised to $335 at Bernstein; 'Strong Q4, Great Setup for 2025'
-
Insulet Corporation (PODD) PT Raised to $293 at Stifel
-
Insulet Corporation (PODD) PT Raised to $324 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $310 at BTIG
-
Insulet (PODD) Tops Q4 EPS by 12c; offers outlook
-
Insulet (PODD) Launches Revolutionary Omnipod 5 in Five More Countries in Europe
-
Insulet Corporation (PODD) PT Raised to $324 at TD Cowen
-
Boston Scientific (BSX) PT Raised to $101 at BTIG
-
Insulet Corporation (PODD) PT Raised to $300 at BTIG
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
Tandem Diabetes (TNDM) and Insulet (PODD) Volatility Attributed to Channel-Check Firm
-
Insulet (PODD) Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Insulet Corporation (PODD) PT Raised to $234 at Barclays
-
Insulet Corporation (PODD) PT Raised to $270 at BTIG
-
Insulet Corporation (PODD) PT Raised to $283 at Citi
-
Insulet (PODD) Tops Q3 EPS by 12c, provides guidance
-
Bernstein SocGen Group Starts Insulet Corporation (PODD) at Outperform

